Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer
Major news: Pembrolizumab combination received approval from Canadian regulatory authority for the treatment of cervical cancer. A piece of encouraging news for cervical cancer patients countrywide.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Efforts are being concentrated on improving the management protocols for immune-checkpoint inhibitor toxicities in Melanoma. This hints at potential advancements in how immunity-related side-effects are handled in skin cancer treatments.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
Significant development: SRN-101 has been granted a fast track designation by FDA for the treatment of recurrent high-grade gliomas, speeding up its pathway to potentially becoming an effective treatment option.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
A breakthrough in multiple myeloma treatment as a new small molecule demonstrates early activity. Offering hope for exciting future advancements in the therapeutics of blood cancer.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
Significant study underway comparing quality of life outcomes between patients treated with Protons versus Photons in OPSCC, aiming to understand which offers better post-treatment lifestyles.
3 Things You Should Know About PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer
The nuances of PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer are discussed, aiming to demystify some important considerations for those affected by the disease.
